Want to see TSE:XRTX full AI Analyst Report?
XRTX Stock Chart & Stats
C$2.95
-C$0.11(-3.73%)
At close: 4:00 PM EDT
C$2.95
-C$0.11(-3.73%)
Day’s Range― - ―
52-Week RangeC$2.43 - C$9.85
Previous CloseN/A
Volume6.91K
Average Volume (3M)11.08K
Market Cap
C$5.16M
Enterprise ValueC$3.22
Total Cash (Recent Filing)C$250.45K
Total Debt (Recent Filing)C$15.07K
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,816,565
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)C$3.25M
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low debt materially reduces financial distress risk for a clinical-stage biopharma. Over the next 2–6 months this structural strength preserves strategic optionality for R&D financing, supports safer execution of trials, and improves bargaining power with potential partners or lenders.
Improving Loss TrendsMeaningful narrowing of operating losses reflects durable cost control or program prioritization. A sustained reduction in burn rate improves runway dynamics, reduces near-term financing frequency, and increases the probability management can advance lead candidates without continual dilutive raises.
Focused Clinical-stage PipelineSpecialization in kidney and metabolic disorders gives the company concentrated scientific expertise and a clearer regulatory and commercial pathway. This niche focus can create durable competitive positioning, easier partner fit for licensing, and higher upside per successful clinical milestone.
Bears Say
No Revenue And Ongoing Net LossesAbsence of operating revenue and recurring net losses is a structural constraint for a clinical-stage firm: continued R&D spend without commercialization means persistent dependence on external capital, which can constrain program timelines and increase dilution risk over multiple financing cycles.
Shrinking Equity BaseA materially reduced equity cushion signals accumulated losses and previous dilution, weakening the company’s ability to absorb setbacks. Over time this thinner capital base limits flexibility, may raise cost of new capital, and amplifies governance and investor pressure during subsequent financings.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow, and a decline in free cash flow versus prior periods, show cash generation is not yet viable. Structurally, this forces reliance on dilutive financing or partner deals to fund trials, slowing execution and increasing long-term shareholder dilution risk.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$2.42 and its highest was C$9.85 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$5.16M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 7 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -C$0.812 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,816,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -C$0.812 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -20.288%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.